Responsive stimulation of the thalamus for idiopathic generalized epilepsy: Results of the randomized controlled NAUTILUS trial through 18 months
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVE: This study was undertaken to evaluate the safety and effectiveness of responsive thalamic stimulation as adjunctive therapy for drug-resistant idiopathic generalized epilepsy (IGE) with generalized tonic-clonic seizures (GTCSs). METHODS: NAUTILUS is a prospective, multicenter, single-blind, randomized sham-controlled pivotal trial. Patients were ≥12 years of age with drug-resistant IGE and ≥2 GTCSs over a 3-month baseline. Bilateral depth leads were targeted to the centromedian thalamus. One month later, patients were randomized to Active (responsive stimulation, n = 44) or Sham (no stimulation, n = 43). The effectiveness evaluation period (EEP) began 3 months postimplant through 1 year. After a second GTCS in the EEP, patients transitioned to open-label active stimulation. The primary safety endpoint was the serious adverse device-related event (SADE) rate at 84 days postimplant. The primary effectiveness endpoint was time-to-second-GTCS during the EEP. Additional endpoints included median percent change in days with any generalized seizure, GTCS frequency, and responder rate (RR). RESULTS: Eighty-seven patients were implanted across 23 US centers. The SADE rate was significantly below the performance goal (6.9%, p < .0001), with no adverse effects on cognition, mood, or sleep. The prespecified primary effectiveness endpoint was not significant. However, a post hoc mixed-effects model considering all EEP days demonstrated greater GTCS reduction in the originally randomized Active group (61%) compared to patients originally randomized to Sham (49%, p = .030). Eighteen-month outcomes included 76.8% median GTCS reduction, 62.5% RR, 40% GTCS-free at that timepoint, and 77.8% median reduction in days with any generalized seizure. More than 90% of patients and 86% of physicians reported improvement on Global Impression of Change scales. SIGNIFICANCE: NAUTILUS is the first randomized controlled neuromodulation trial in IGE. Responsive thalamic stimulation provided a clinically meaningful and durable reduction in seizures with an acceptable safety profile, offering a much-needed option for drug-resistant IGE.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.
- Titre Crossref
- Responsive stimulation of the thalamus for idiopathic generalized epilepsy: Results of the randomized controlled <scp>NAUTILUS</scp> trial through 18 months
- Date Crossref
- 03/06/2026
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
The University of Kansas Health System pays non établi dans la noticeÉtablissement de santé
-
Vanderbilt University Medical Center pays non établi dans la noticeÉtablissement de santé
-
The University of Texas Health Science Center pays non établi dans la noticeUniversité ou école supérieure
-
University of Minnesota System pays non établi dans la noticeUniversité ou école supérieure
-
University of Colorado Denver pays non établi dans la noticeUniversité ou école supérieure
-
University of New Mexico pays non établi dans la noticeUniversité ou école supérieure
-
University of Louisville pays non établi dans la noticeUniversité ou école supérieure
-
University of Utah pays non établi dans la noticeUniversité ou école supérieure
-
Massachusetts General Hospital pays non établi dans la noticeÉtablissement de santé
-
Indiana University Health pays non établi dans la noticeÉtablissement de santé
-
Indiana University – Purdue University Indianapolis pays non établi dans la noticeUniversité ou école supérieure
-
University of Pittsburgh Medical Center pays non établi dans la noticeÉtablissement de santé
The University of Kansas Health System, Vanderbilt University Medical Center et The University of Texas Health Science Center, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.